Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43rd...

Key Takeaway: Alkermes plc announced that CEO Richard Pops will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The presentation will include a corporate overview and a question-and-answer session. Investors can access the live webcast on the company's website, which will be available for 14 days post-event.
Price reaction · baseline $28.76 (2024-12-31 close) · hit after-hours · clean, no other ALKS news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • CEO Richard Pops will provide a corporate overview at a major conference.
  • The presentation includes a Q&A session, allowing for investor engagement.
  • Alkermes has a diverse portfolio in neuroscience, indicating strong market presence.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
3.3%
average across 7 past catalysts
Lead asset
N1539
Phase 2 · Hysterectomy

Full Press Release Details

DUBLIN , Jan. 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS ) announced today that its Chief Executive Officer, Richard Pops , will provide a corporate overview and update at the 43 rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 15, 2025 at 11:15 a.m. PST ( 2:15 p.m. EST / 7:15 p.m. GMT ), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia . Headquartered in Ireland , Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio . For more information, please visit Alkermes ' website at www.alkermes.com .

Frequently Asked Questions

When will Alkermes present at the J.P. Morgan Conference?

Alkermes will present on January 15, 2025, at 11:15 a.m. PST.

Who will represent Alkermes at the conference?

CEO Richard Pops will provide the corporate overview.

How can I access the Alkermes presentation?

The presentation will be available via a live webcast on Alkermes' website.

Will there be a Q&A session during the presentation?

Yes, a question and answer session will follow the presentation.

Last updated: Jan 2, 2025